Programs & Intitiatives
The Cystic Fibrosis (CF) Foundation is committed to finding a cure for CF. Since 2004, the CF Foundation has funded NDRI to provide a reliable source of human tissues from CF donors with different genotypes to facilitate research and drug development. NDRI has continuously met those needs by providing countless high-quality biospecimens, which the foundation can use in studies to further promote individualized treatment and specialized care for individuals affected by the disease.
Vertex Pharmaceuticals used cells derived from biospecimens we supplied to develop the FDA-approved drug Kalydeco® (ivacaftor), one of the first drugs to give patients with CF an opportunity to lead a full and productive life.